Y
Yu Hu
Researcher at Huazhong University of Science and Technology
Publications - 487
Citations - 34645
Yu Hu is an academic researcher from Huazhong University of Science and Technology. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 37, co-authored 435 publications receiving 24865 citations. Previous affiliations of Yu Hu include Chinese Ministry of Education & Guangzhou Medical University.
Papers
More filters
Journal ArticleDOI
Characterization and commissioning of a Leksell Gamma Knife ICON system for framed and frameless stereotactic radiosurgery
Yu Hu,Susannah V. Hickling,Jing Qian,Charles Robert Blackwell,Luke B. McLemore,Erik Tryggestad +5 more
TL;DR: End‐to‐end (E2E) testing using EBT3 film was designed to evaluate both dosimetric and geometric accuracy for hypothetical framed and frameless workflows; geometric accuracy of framed treatments using CBCT‐defined stereotactic coordinates was shown to be slightly improved in comparison with those defined using conventional CT.
Journal Article
Bond behavior of plain round bars in concrete under complex lateral pressures
TL;DR: In this article, the authors presented an experimental investigation into the bond behavior of plain round bars subjected to uniaxial and baoxial lateral pressures with different pressure ratios, and showed that the residual and ultimate bond strength increase with the increase of the average lateral pressure, but their ratio stays invariable.
Journal ArticleDOI
Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma
TL;DR: In this article, the authors explored the relationship between pretreatment cytokine status and overall survival and established a prognostic nomogram incorporating cytokines in newly diagnosed multiple myeloma (NDMM) patients.
Book ChapterDOI
COVID-19 Diagnosis
TL;DR: The rational use of laboratory indicators is of great significance in guiding clinical diagnosis and treatment and the laboratory staff should be careful to determine biosecurity measures to avoid infection based on the operational risk level of different test items.
Journal ArticleDOI
Reduced-intensity versus Myeloablative Conditioning Regimens for Younger Adults with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A systematic review and meta-analysis.
TL;DR: It might be concluded that RIC is a feasible treatment option for adults with AML or MDS younger than 66 years, particularly those with intermediate-risk disease.